Compare Meta Platforms Inc (META) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Meta Platforms Inc trades at $641.91 (market cap $1.64T), while State Street SPDR S&P Biotech ETF trades at $154.41. The key difference: Meta Platforms Inc pays a 0.33% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Meta Platforms Inc nearer its low. Which is the better fit depends on your goals.
| META | XBI | |
|---|---|---|
Market Cap | $1.64T | — |
Volume | 24,093,972 | — |
Sector | Media | Broad Market / Factor |
52-Week High | $790.00 | $164.28 |
52-Week Low | $525.72 | $85.16 |
Enterprise Value | $1.65T | — |
Dividend Yield | 0.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms (META) trades at $643.81, down 0.34% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates robust fundamentals with 2025 revenue of $201B, net income of $60.5B, and impressive profitability margins including 81.9% gross margin and 32.8% net margin. Recent catalysts include the launch of Muse Spark AI model and consistent earnings beats, with Q1 2026 EPS of $10.44 significantly exceeding expectations of $6.70.
The outlook remains positive with analyst consensus price target of $817.32 representing 27% upside potential. Key opportunities include AI monetization through Muse Spark and strong advertising revenue growth, while risks involve ongoing litigation regarding youth addiction claims and elevated capital expenditures for AI infrastructure. Wall Street maintains strong bullish sentiment with 79% buy ratings.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
